Replies to post #142491 on Biotech Values

[p3analyze]

>>so I imagine if tested much earlier or in combo, we would be seeing drastically higher responses.<<

This is an important point the MD made on the call. They didn't expect to see any responder, didn't see any in the recently approved eribulin and ixabepilone (which both demonstrated 10% confirmed response rate in triple-negative setting - albeit earlier line), but instead saw responses coming from drugs they didn't expect to see (eg Gemzar was named- yes good old Lilly drug!).

They would have really to dig deeper into those Triple negative responders and perhaps they would find an explanation of why.